KD025: Phase II started

Kadmon began the open-label, U.S. Phase II Study 206 to evaluate 200 mg KD025 twice daily and 400 mg KD025 once daily for 12 weeks in about 24 patients. Kadmon has exclusive, worldwide rights to the c...